NCT04668235View on ClinicalTrials.gov

Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected)

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 23, 2021

Primary Completion Date

August 10, 2022

Study Completion Date

August 10, 2022

Conditions
COVID-19
Interventions
DRUG

AZVUDINE

5 tablets QD + standard treatment for up to 14 days

DRUG

AZVUDINE placebo

5 tablets QD + standard treatment for up to 14 days

Trial Locations (1)

Unknown

Santa Casa de Misericordia de Campos, Campos dos Goytacazes

Sponsors
All Listed Sponsors
collaborator

GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil

UNKNOWN

collaborator

UNIVERSIDADE ESTADUAL DO NORTE FLUMINENSE (UENF), Brazil

UNKNOWN

lead

HRH Pharmaceuticals Limited

OTHER

NCT04668235 - Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected) | Biotech Hunter | Biotech Hunter